Scope and Claims Analysis of US Patent 4,795,751 (United States) and the U.S. Patent Landscape for Its Quinoline-3-Carboxylic Acid Antibacterial Compounds

US Patent 4,795,751 is an antibacterials composition-and-method patent that claims (i) a defined family of substituted quinoline-3-carboxylic acids (plus pharmaceutically acceptable esters and salts), and (ii) antibacterial compositions and treatment methods that use members of those families. The independent claim structure is centered on “a member selected from the group consisting of” multiple chemical subfamilies plus downstream formulation and use claims. The scope is medium-to-broad on the chemical genus because the claim language uses variable substitution points (R1/R2/R3) and covers pharmaceutically acceptable salts/esters.

What does US 4,795,751 claim: compound genus, salts/esters, and downstream composition/use?

Short answer: The patent covers substituted quinoline-3-carboxylic acids defined by two separate “member selected from the group consisting of” formula clusters, and it extends protection to antibacterial compositions and methods of treating bacterial infections using those compounds.

Claim 1 and Claim 6: “member selected from the group consisting of” two generic chemical formula clusters

Claim 1 covers a “member” selected from:

A compound of a formula (Image in the claim) with substitution limitations:

R1 is hydrogen or methyl
R2 is methyl or fluoromethyl
R3 is hydrogen or methyl

A pharmaceutically acceptable ester of that compound
A pharmaceutically acceptable salt of that compound (or its ester)

Claim 6 is another “member selected from” cluster with a different formula set and variable restrictions:

R1 is hydrogen or methyl
R2 is hydrogen or methyl or fluoromethyl
R3 is hydrogen or methyl
and again includes esters and salts.

Practical claim scope implication: The independent claims are not limited to one named structure. They cover a defined structural neighborhood using variable substitution points, while still tying coverage to the same quinoline-3-carboxylic acid scaffold and substitution pattern within the formula.

Claims 2–3 and 7–9: named exemplars within the genus

These claims narrow to specific, enumerated compounds (or their pharmaceutically acceptable acid addition salts):

Claim 2: 5-Amino-1-cyclopropyl-6,8-difluoro-7-(3-methyl-1-piperazinyl)-1,4-dihydro-4-oxoquinoline-3-carboxylic acid (or acid addition salt)
Claim 3: same core with 7-(3,5-dimethyl-1-piperazinyl)
Claim 7: 1-Cyclopropyl-5,6,8-trifluoro-7-(1-piperazinyl) (or acid addition salt)
Claim 8: same with 7-(4-methyl-1-piperazinyl)
Claim 9: same with 7-(3-methyl-1-piperazinyl)

Practical implication: The genus claims (1 and 6) likely have broader coverage than these exemplars. The exemplar claims can be used to anchor infringement positions even if an accused product is argued to be outside the genus variable ranges.

Claims 4–5 and 10–11: antibacterial compositions and treatment methods

Claim 4: An antibacterial composition comprising an antibacterially effective amount of a compound (or ester/salt) as defined in claim 1 + a pharmaceutically acceptable carrier.
Claim 5: A method for treating bacterial infectious disease by administering an antibacterially effective amount of that same compound family to a warm-blooded animal.
Claim 10: Composition using a compound (or ester/salt) as defined in claim 6 + carrier.
Claim 11: Method of treatment using the claim 6 compound family.

Practical implication: These are classic “product-by-composition” and “use” claims. Even if a formulation lacks a specific excipient, infringement can still be argued if the accused product contains a compound within the claimed family and includes a pharmaceutically acceptable carrier.

How are the substitution variables likely interpreted: where is the boundary of infringement?

The key legal-technical boundaries in claims 1 and 6 are the substitution variables R1/R2/R3 tied to the formula positions in the drawings:

R1 is hydrogen or methyl in both claims 1 and 6
R2 varies:
- Claim 1 limits R2 to methyl or fluoromethyl
- Claim 6 allows R2 to be hydrogen, methyl, or fluoromethyl
R3 is hydrogen or methyl in both claims 1 and 6

Because the claim language uses explicit allowed alternatives, infringement requires the accused compound to match one of the allowed substituents at each relevant position. If R2 is something other than the allowed set, the compound can fall outside the genus even if it has the same overall scaffold.

Esters and salts expand the practical coverage surface

The claims explicitly include:

pharmaceutically acceptable esters
pharmaceutically acceptable salts, including “pharmaceutically acceptable acid addition salts” for the named compounds

This typically matters in prosecution and enforcement because:

drug products often commercialize as salts (e.g., HCl, mesylate) or prodrugs/esters.
if an accused product is marketed as a salt or ester, the patentee can still argue literal infringement if the underlying active is a compound meeting the formula requirements.

What is the scope in plain terms: which scaffold is protected?

Across the enumerated compounds and the formula clusters, the protected scaffold is:

a 1-cyclopropyl-substituted (in the named compounds)
amino-substituted quinoline derivative
bearing fluoro substitution at defined positions (difluoro or trifluoro patterns in the named compounds)
with a piperazinyl substituent at the 7-position (varying methyl substitution patterns)
and a quinoline-3-carboxylic acid functional group (or ester/salt derivatives)

The independent claims are built to cover variations in the substituents at specific points rather than claiming a single target molecule.

What “member selected from” means for claim construction and infringement strategy

“A member selected from the group consisting of …” is a closed-group selection phrase. Under typical claim construction, the patentee must show the accused product is one of the listed categories:

a compound satisfying the specific formula variable allowances,
an acceptable ester of that compound,
an acceptable salt of that compound (or its ester).

Enforcement leverage: The patentee has a clear pathway:

map accused API structure to the formula variable set (R1/R2/R3),
then show salt/ester form is “pharmaceutically acceptable,” and
connect antibacterial use via composition or dosing regimen.

What does the patent landscape likely look like in the U.S. for this scaffold?

Because your prompt provides only the claim text and the patent number, and not the drug name, applicants/assignees, FDA product, or prosecution history, a complete U.S. landscape mapping (family members, continuation scope, other patents on the same active, Orange Book coverage, and litigation) cannot be produced from the provided information alone.

Under the constraints for an accurate patent landscape report, the only defensible “landscape” elements that can be derived purely from the claims are structural scope and likely downstream IP categories that competitors would typically evaluate:

Adjacent U.S. patent categories competitors usually clear for this type of antibacterial scaffold

Even without naming specific later patents, the relevant freedom-to-operate diligence areas that flow directly from these claim types are:

API form variants: other salts, polymorphs, and ester prodrugs for the same quinoline-3-carboxylic acid core.
Formulation: sustained release, specific carriers, and dosing unit presentations (often argued under composition claims like 4 and 10).
Method-of-use: broader indications or dosing regimens (often constrained by claims 5 and 11).
Synthesis methods: if later process patents exist, they do not usually avoid infringement of the composition/use claims but can affect manufacturing freedom.
Overlapping chemical genera: continuations or related filings that expand or narrow the R1/R2/R3 substitution space.

Key claim scope callouts that matter for licensing and litigation

1) Chemical genus breadth is defined by R2 limits

Claim 1 is tighter on R2: methyl or fluoromethyl
Claim 6 is broader: hydrogen, methyl, or fluoromethyl

If an accused molecule differs only by swapping R2 to hydrogen (or omitting a methyl/fluoromethyl substituent at that position), it could land inside claim 6’s genus but outside claim 1’s genus.

2) Salt/ester coverage removes a common design-around

A typical generic strategy is to commercialize a different salt. These claims are explicitly drafted to cover “pharmaceutically acceptable salts” and “pharmaceutically acceptable esters,” limiting the ability to avoid infringement by simple salt selection, unless the competitor changes the underlying compound so it no longer matches the allowed formula substitutions.

3) Composition and method claims create dual enforcement vectors

If an accused product sells a formulation containing the claimed API within the covered genus, claims 4 and 10 are directly relevant.
If an accused product is sold with antibacterial indications and the dosing corresponds to the “warm-blooded animal” method, claims 5 and 11 can be asserted.

Timeline framework: how exclusivity typically interacts with these claims

A precise legal timeline (filing date, issuance date, expiration, PTA, and exclusivity events) requires bibliographic data not included in your prompt. On structural grounds, the core exclusivity on the active compound is tied to:

the filing and issuance of US 4,795,751 and any continuation family,
any patent term adjustment,
any regulatory exclusivity associated with the first FDA approval of the corresponding drug product,
and later-introduced patents that may extend coverage via formulations or specific uses.

Without the bibliographic record and regulatory mapping, a factual expiration and “generic entry risk” schedule cannot be stated.

Tables: claim coverage map (structure to legal coverage)

Claim-to-scope matrix

Claim	Scope type	What is claimed	Core coverage boundary
1	Chemical genus + salts/esters	Formula compound with R1/R2/R3 limits + acceptable esters/salts	R1 ∈ {H, Me}; R2 ∈ {Me, fluoromethyl}; R3 ∈ {H, Me}
2	Specific compound	5-Amino-1-cyclopropyl-6,8-difluoro-7-(3-methyl-1-piperazinyl)-...-3-carboxylic acid + acid addition salt	Exact substituent pattern
3	Specific compound	Same but 7-(3,5-dimethyl-1-piperazinyl)	Exact substituent pattern
4	Composition	Antibacterial-effective amount of claim 1 member + pharmaceutically acceptable carrier	Requires accused formulation contains covered API
5	Method-of-use	Administer claim 1 member to warm-blooded animal for bacterial infection	Requires use/dosing of covered API
6	Chemical genus + salts/esters	Another formula cluster with different R2 allowances + acceptable esters/salts	R1 ∈ {H, Me}; R2 ∈ {H, Me, fluoromethyl}; R3 ∈ {H, Me}
7	Specific compound	1-cyclopropyl-5,6,8-trifluoro-7-(1-piperazinyl)-...-3-carboxylic acid + acid addition salt	Exact substituent pattern
8	Specific compound	Same but 7-(4-methyl-1-piperazinyl)	Exact substituent pattern
9	Specific compound	Same but 7-(3-methyl-1-piperazinyl)	Exact substituent pattern
10	Composition	Antibacterial-effective amount of claim 6 member + pharmaceutically acceptable carrier	Requires accused formulation contains covered API
11	Method-of-use	Administer claim 6 member to warm-blooded animal	Requires use/dosing of covered API

What patents protect similar chemical spaces: how competitors typically design around

Based strictly on the claim language, a competitor attempting to avoid infringement would focus on one or more of the following, each of which targets the claim boundary:

Change the quinoline-3-carboxylic acid scaffold substitution pattern so that at least one of R1/R2/R3 falls outside the allowed sets in claim 1 or claim 6.
Remove/alter the functional group so the compound is no longer an ester/salt derivative of the claimed acid (this is hard because the claims already include esters and salts of the covered compounds).
Avoid providing an antibacterial composition with a covered API (for composition claims), and/or avoid claimed dosing for bacterial infections (for method claims).

These are structural levers in the claims; they are not substitute for an actual invalidity or noninfringement analysis.

Key Takeaways

US 4,795,751 is built around a substituted quinoline-3-carboxylic acid antibacterial family.
The strongest literal scope comes from claims 1 and 6 (genus-by-variable substitution) plus explicit coverage of pharmaceutically acceptable esters and salts.
Claims 2–3 and 7–9 lock down specific piperazinyl/fluoro substitution exemplars that sit within those genera.
Claims 4–5 and 10–11 add enforcement reach through antibacterial composition and method-of-treatment claims for warm-blooded animals.
The main structural boundary for chemical infringement is the allowed sets of R1/R2/R3, with claim 6 generally broader on R2 (including hydrogen).

FAQs

1) Does US 4,795,751 cover salt forms of the claimed quinoline-3-carboxylic acids?
Yes. Claims 1 and 6 include “pharmaceutically acceptable salts” of the covered compounds (and salts of the covered esters).

2) Can a competitor avoid infringement by switching from a free acid to an acid addition salt?
Not by salt selection alone, because the claims already cover pharmaceutically acceptable salts (including acid addition salts for the named compounds).

3) What claim is most important for direct API infringement risk?
Claims 1 and 6, because they define the chemical genus by variable substitution and include esters and salts.

4) Do the composition and method claims require a specific formulation?
Claim 4 and 10 require a pharmaceutically acceptable carrier, but do not limit the carrier type beyond “pharmaceutically acceptable.” Claim 5 and 11 are triggered by administration of a covered compound family to treat bacterial infections in warm-blooded animals.

5) Is the patent limited to the specifically named compounds only?
No. The named compounds (claims 2, 3, 7, 8, 9) are additional specific members; the independent claims protect broader genus language.

References

No sources were cited because the prompt did not include bibliographic or prosecution/regulatory data needed for a defensible patent landscape with verifiable external references.

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Japan	60-242257	Oct 29, 1985
Japan	60-285323	Dec 17, 1985
Japan	61-32627	Feb 17, 1986

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	0221463	⤷ Start Trial	SPC/GB95/012	United Kingdom	⤷ Start Trial
European Patent Office	0375658	⤷ Start Trial	SPC/GB98/036	United Kingdom	⤷ Start Trial
European Patent Office	0375658	⤷ Start Trial	C300014	Netherlands	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 4,795,751

Summary for Patent: 4,795,751